NCT00271505 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer


Sponsors: M.D. Anderson Cancer Center Genentech	Phases: Phase II
Indications	Acronym:
Non-small Cell Lung Cancer
Age Groups: Adult Senior	Gender: Both
Names: Drug: Bevacizumab (Avastin) Drug: Carboplatin Drug: Docetaxel	Enrollment: 50

Additional information about NCT00271505.